Efficacy and safety of different once-weekly glucagon-like peptide-1 receptor agonists-A systematic review and Bayesian network meta-analysis
EndocrinologiaSobre o estudo
- Desenho
- Revisão sistemática
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Diabetes research and clinical practice
- Publicado em
- 24 out 2025
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Efficacy and safety of different once-weekly glucagon-like peptide-1 receptor agonists-A systematic review and Bayesian network meta-analysis
Ying Xu, Guikai Ji, Chenyang Shi, Yijiong Tan, Li Wang, Yaxing Gui
Descritores MeSH
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Glucagon-Like Peptide-1 Receptor Agonists
- Blood Glucose
- Drug Administration Schedule
- Glucagon-Like Peptides
- Glycated Hemoglobin
- Humans
- Immunoglobulin Fc Fragments
- Recombinant Fusion Proteins
Veja também
Estudos relacionados
- Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials
- Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis